In this Article we will talk about Akms Drugs and Pharmaceuticals Limited IPO. Akms Drugs and Pharmaceuticals Limited IPO will open on 30th July 2024 and close on 1st August 2024. This company is a significant pharmaceutical contract development and manufacturing organization.
The book-built issue of Akums Drugs and Pharmaceuticals is valued at Rs 1,856.74 crores. The offering consists of 1.73 crore shares for sale, totalling Rs 1,176.74 crores, and a new issue of 1 crore shares, totalling Rs 680.00 crores.
The IPO price range for Akums Drugs & Pharmaceuticals is ₹646 to ₹679 per share. Applications must have a minimum lot size of 22 shares. Retail investors are required to invest a minimum of ₹14,938. For both sNII and bNII, the minimum lot size investment is ₹209,132 for 14 lots (308 shares) and ₹1,000,846 for 67 lots (1,474 shares).
Up to 243,902 shares of the issuance are reserved for workers and are available at a discount of Rs 64 from the issue price.
About Akms Drugs and Pharmaceuticals Limited
Akms Drugs and Pharmaceuticals was founded in 2004 is a significant pharmaceutical contract development and manufacturing organization which Offers a wide range of pharmaceutical goods and services in India and globally. The company provides comprehensive solutions that cover product development, manufacturing, formulation research and development, regulatory dosage preparation and submissions, as well as a variety of testing services.
Additional Acquires Branded Pharmaceuticals and Active Pharmaceutical Ingredients Manufactures and sells as a CDMO Acquires a wide variety of dosage forms Manufactures including tablets, capsules, liquid medications, vials, ampulses, blow fill closures, topical treatments, eye drops, dry powders, injections and gummy bears Among Others The firm has 4,146 commercial IQ businesses and 26 formulations for the company.
In terms of sales generated, the firm operates 10 manufacturing units for its CDMO business with a total annual production capacity of 49.2 billion units by the age of March 31, 2024.
A new injectables facility will be operational in fiscal 25. Several ACMS facilities are accredited by worldwide regulatory authorities including European Good Manufacturing Practices World Health Organization Good Manufacturing Practices and United States National Sanitation Foundation. ACMS Drugs & Pharmaceuticals employs 16,127 people, including 7,388 full-time employees and 8,739 contract workers.
Financials
| Period Ended | 2024 | 2023 | 2022 |
| Revenue | 4212.21 | 3700.93 | 3694.52 |
| Profit After Tax | 0.79 | 97.82 | -250.87 |
| EBITDA | 157.01 | 384.05 | -69.08 |
| Total Assets | 3516.37 | 3266.53 | 3069.05 |
| Share Capital | 28.6 | 28.6 | 14.30 |
| Total Liabilities | 491.56 | 536.97 | 357.95 |
| Amount in ₹ Crore | |||
Disclaimer: Socialreed offers news on the stock market for educational reasons. It’s not meant to be taken as financial advice. Before making investing decisions, readers should speak with a licensed financial advisor.
